From: Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis
Characteristic | 977A | 977B | ||
---|---|---|---|---|
Number | % | Number | % | |
Age at diagnosis (years) | ||||
≤ 40 | 89 | 9 | 80 | 8 |
41-50 | 197 | 20 | 207 | 21 |
> 50 | 494 | 51 | 492 | 50 |
unknown | 197 | 20 | 198 | 20 |
Distant metastasis-free survival (years) | ||||
no recurrence, < 5 | 617 | 63 | 648 | 66 |
recurrence, < 5 | 198 | 20 | 184 | 19 |
lost to follow-up, < 5 | 111 | 11 | 96 | 10 |
no recurrence, 5-to 10 | 245 | 25 | 253 | 26 |
recurrence, 5 to 10 | 51 | 5 | 49 | 5 |
lost to follow-up, 5 to 10 | 357 | 37 | 395 | 40 |
Estrogen receptor status | ||||
positive | 657 | 67 | 686 | 70 |
negative | 220 | 23 | 181 | 19 |
unknown | 100 | 10 | 110 | 11 |
Lymph node status | ||||
negative | 749 | 77 | 749 | 77 |
positive | 217 | 22 | 220 | 23 |
unknown | 11 | 1 | 8 | 1 |
Histologic grade | ||||
well differentiated | 105 | 11 | 131 | 13 |
moderately differentiated | 317 | 31 | 335 | 34 |
poorly differentiated | 316 | 32 | 260 | 27 |
unknown | 239 | 24 | 251 | 26 |
Tumor size (cm) | ||||
≤ 2.0 | 482 | 49 | 505 | 52 |
2.1 to 5.0 | 363 | 37 | 356 | 36 |
> 5.0 | 29 | 3 | 19 | 2 |
unknown | 103 | 11 | 97 | 10 |
Adjuvant treatment | ||||
yes | 478 | 49 | 488 | 50 |
no | 490 | 50 | 484 | 50 |
tamoxifen monotherapy (ER+) | 318 | 33 | 332 | 34 |
chemotherapy | 141 | 14 | 140 | 14 |
unknown | 9 | 1 | 5 | 1 |
Molecular subtypes | ||||
Basal | 243 | 25 | 217 | 22 |
HER2-E | 93 | 10 | 81 | 8 |
Claudin-Low | 48 | 5 | 44 | 5 |
Luminal A | 264 | 27 | 303 | 31 |
Luminal B | 185 | 19 | 188 | 19 |